Comparative Pharmacology
Head-to-head clinical analysis: APOKYN versus PRAMIPEXOLE DIHYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APOKYN versus PRAMIPEXOLE DIHYDROCHLORIDE.
APOKYN vs PRAMIPEXOLE DIHYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apomorphine is a non-ergoline dopamine agonist that stimulates dopamine D2 and D1 receptors. It also activates D3, D4, and D5 receptors and has some serotonergic and adrenergic activity.
Non-ergoline dopamine agonist that selectively binds to D2 and D3 dopamine receptors, particularly D3, in the striatum and substantia nigra, mimicking dopamine's effects to improve motor function in Parkinson's disease.
Subcutaneous injection: 0.2 mL (2 mg) as a test dose, then 0.1-0.6 mL (1-6 mg) as needed for episodes of hypomobility; maximum single dose: 0.6 mL (6 mg); maximum daily dose: 2.0 mL (20 mg).
0.125 mg orally three times daily, titrated as tolerated to maximum 4.5 mg/day
None Documented
None Documented
Terminal elimination half-life approximately 30–60 minutes (range 0.5–1 hour); clinically, rapid clearance necessitates continuous or frequent dosing for sustained effect
Terminal half-life: 8–12 hours in young adults; up to 15–18 hours in elderly. Clinical context: Once-daily dosing; steady-state in 2–4 days.
Renal (approx. 90% as metabolites and unchanged drug; <5% unchanged in urine); biliary/fecal (minor, <10%)
Renal: ~90% unchanged in urine; biliary/fecal: ~2%.
Category C
Category A/B
Dopamine Agonist
Dopamine Agonist